CN114592011B - 一种ptdss2条件性基因敲除小鼠模型的构建方法 - Google Patents
一种ptdss2条件性基因敲除小鼠模型的构建方法 Download PDFInfo
- Publication number
- CN114592011B CN114592011B CN202210502574.3A CN202210502574A CN114592011B CN 114592011 B CN114592011 B CN 114592011B CN 202210502574 A CN202210502574 A CN 202210502574A CN 114592011 B CN114592011 B CN 114592011B
- Authority
- CN
- China
- Prior art keywords
- mouse
- sgrna
- seq
- ptdss2
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000010172 mouse model Methods 0.000 title claims abstract description 13
- 101001102154 Homo sapiens Phosphatidylserine synthase 2 Proteins 0.000 title description 8
- 102100039300 Phosphatidylserine synthase 2 Human genes 0.000 title description 8
- 238000010276 construction Methods 0.000 title description 8
- 238000003209 gene knockout Methods 0.000 title description 5
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 35
- 101150003349 Ptdss2 gene Proteins 0.000 claims abstract description 17
- 108091033409 CRISPR Proteins 0.000 claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 16
- 238000013518 transcription Methods 0.000 claims abstract description 11
- 230000035897 transcription Effects 0.000 claims abstract description 11
- 238000005516 engineering process Methods 0.000 claims abstract description 10
- 238000011813 knockout mouse model Methods 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 8
- 230000008685 targeting Effects 0.000 claims abstract description 8
- 101100299628 Mus musculus Ptdss2 gene Proteins 0.000 claims abstract description 6
- 238000000338 in vitro Methods 0.000 claims abstract description 6
- 239000013598 vector Substances 0.000 claims abstract description 6
- 238000012216 screening Methods 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 5
- 238000009395 breeding Methods 0.000 claims description 4
- 230000001488 breeding effect Effects 0.000 claims description 4
- 238000003205 genotyping method Methods 0.000 claims description 4
- 241000581650 Ivesia Species 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 210000000805 cytoplasm Anatomy 0.000 claims description 2
- 235000013601 eggs Nutrition 0.000 abstract description 7
- 238000010354 CRISPR gene editing Methods 0.000 abstract description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 7
- 238000011160 research Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 238000012239 gene modification Methods 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1288—Transferases for other substituted phosphate groups (2.7.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/124—Animal traits, i.e. production traits, including athletic performance or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/08—Transferases for other substituted phosphate groups (2.7.8)
- C12Y207/08029—L-Serine-phosphatidylethanolamine phosphatidyltransferase (2.7.8.29)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Environmental Sciences (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明涉及一种使用CRISPR/Cas9技术构建PTDSS2基因条件性敲除小鼠模型的方法，其包括：1、设计针对鼠源PTDSS2基因Exon2‑Exon3的sgRNA，2、利用体外转录技术获得上述sgRNA，3、将打靶载体、上述sgRNA、Cas9蛋白共注射或共电转至小鼠受精卵等步骤。与传统ES打靶小鼠模型相比，本发明首次构建的PTDSS2基因条件性敲除小鼠模型具有高效、快捷、简便、成本便宜等特点，且可以通过Cre来调控基因在特定的组织或特定时间进行表达。
Description
技术领域
本发明属于基因工程领域，具体涉及一种PTDSS2条件性基因敲除小鼠模型的构建方法及其应用。
背景技术
CRISPR/Cas9技术是通过设计特异性sgRNA实现特异性的DNA识别，并且在靶向位置完成切割，再通过细胞本身的DNA修复机制，完成断裂处的修复，从而实现目标基因的“编辑”。而随着CRISPR/Cas9技术的发展和研究的深入，其被广泛应用于构建转基因的模式动物（主要为基因编辑小鼠），从而为临床前提供动物层面治疗的基础研究。
人类疾病的发病机制研究和筛选有效的治疗药物均需要进行大量临床前试验。由于直接利用人细胞及组织进行临床前相关研究受到伦理方面的限制，动物模型就成为人类生物学研究的替代选择。小鼠具有体积小、易维持与操作、繁殖周期短、与人在基因组和生理学等特征方面相似，以及已经有相应成熟的基因修饰技术等优势，因此成为广泛应用的哺乳动物模式生物系统。但由于小鼠生理特征与人存在较多差异，利用动物模型得到的实验结果有时不能适用到人体上。然而利用基因修饰或细胞与组织移植的方法，将人类基因或细胞组织“放置”在小鼠模型上所制备的人源化小鼠模型（即带有人类功能性基因、人类细胞或组织的小鼠模型），极大程度上模拟人类基因或细胞组织的相关活动，大大提高了这类小鼠模型作为模拟某些人类疾病的有效性。
PTDSS2（Phosphatidylserine Synthase 2）是一种蛋白质编码基因，该基因编码的蛋白质能够催化磷脂酰乙醇胺转化为磷脂酰丝氨酸。磷脂酰丝氨酸是一种结构膜磷脂，在细胞信号传导、凝血和凋亡中起作用，该基因的一个重要旁系同源物是PTDSS1。目前关于PTDSS2机制研究比较少，CKO小鼠模型有利于进行相应分子以及功能等方面的研究。
PTDSS2 Cas9-CKO小鼠是利用基因修饰的方法，在小鼠的PTDSS2基因上的特定位点插入LoxP，将flox小鼠与表达Cre重组酶的小鼠交配，利用Cre-LoxP系统获得PTDSS2基因条件性敲除小鼠，同时通过Cre诱导可以实现在特定的组织或者特定时间对PTDSS2基因的敲除。
目前暂未检索到采用CRISPR/Cas9技术构建PTDSS2基因条件性敲除小鼠的相关报道。
发明内容
为解决上述技术问题，本发明包括以下几个方面：
本发明的第一方面提供一种PTDSS2基因条件性敲除小鼠模型构建方法，该方法包括如下步骤：
（1）设计针对鼠源PTDSS2基因Exon2-Exon3的sgRNA；
（2）利用体外转录技术获得上述sgRNA；
（3）将打靶载体、步骤（2）获得的sgRNA、Cas9蛋白共注射或共电转至小鼠受精卵细胞质或细胞核中，并将该受精卵移植至假孕小鼠，对假孕生仔鼠进行基因型鉴定，筛选成功插入正确人源片段的阳性F0小鼠；
（4）F0小鼠与背景鼠配繁获得F1小鼠，对F1代鼠尾进行基因鉴定，筛选出PTDSS2基因条件性敲除小鼠模型。
优选的，所述步骤（1）中两端sgRNA识别位点分别位于小鼠PTDSS2基因的第二个外显子之前和第三个外显子之后。
优选的，所述步骤（1）中sgRNA的基因序列为SEQ ID NO.1、SEQ ID NO.2、SEQ IDNO.3和SEQ ID NO.4中的一个或多个。
更优选的，所述步骤（1）中sgRNA的基因序列为SEQ ID NO.1和SEQ ID NO.2。
优选的，所述步骤（2）中以sgRNA-F、sgRNA-R为引物对，puc57-sgRNA质粒为模板进行PCR，PCR产物纯化制备sgRNA转录模板，并经过体外转录得到sgRNA。
优选的，所述步骤（2）中的引物对选自SEQ ID NO.5和SEQ ID NO.6，SEQ ID NO.7和SEQ ID NO.8，SEQ ID NO.9和SEQ ID NO.10，SEQ ID NO.11和SEQ ID NO.12所示序列对中一对或多对。
更优选的，所述步骤（2）中的引物对如SEQ ID NO.5和SEQ ID NO.6，以及SEQ IDNO.7和SEQ ID NO.8所示。
优选的，所述步骤（2）中的PCR反应体系如下：
优选的，所述步骤（2）中的PCR反应条件如下：
优选的，所述步骤（3）中提供受精卵的小鼠和假孕小鼠的品系为C57BL/6J。
优选的，所述步骤（3）中F0小鼠基因型鉴定使用的5’端鉴定引物如SEQ ID NO.13和SEQ ID NO.14所示，3’端鉴定引物如SEQ ID NO.15和SEQ ID NO.16所示。
优选的，所述步骤（3）中F0小鼠基因型鉴定使用的PCR反应条件如下：
优选的，所述步骤（3）中F0小鼠基因型鉴定使用的PCR反应体系如下：
本发明的第二方面提供模型构建方法得到的小鼠在研究PTDSS2基因相关功能和作用机制中的应用。
优选的，所述应用是非诊断和非治疗目的的。
本发明的第三方面提供上述构建方法得到的小鼠在筛选用于治疗与PTDSS2基因相关疾病的药物中的应用。
优选的，所述应用是非诊断和非治疗目的的。
本发明产生的有益效果：
与传统ES打靶小鼠模型相比，本发明的PTDSS2基因条件性敲除小鼠模型具有高效、快捷、简便、成本便宜等特点，且CKO模型可以通过Cre来调控基因在特定的组织或特定时间进行表达，可以满足小鼠模型在不同研究方向的需求，同时节省了时间及成本。
附图说明
图1为本发明F0代小鼠PTDSS2-CKO 5端、3端与野生型鉴定电泳图（DNA Marker条带：600bp\500bp\400bp\300bp\200bp\100bp）；
图2为本发明F1代小鼠PTDSS2-CKO 5端、3端与野生型鉴定电泳图（DNA Marker条带：600bp\500bp\400bp\300bp\200bp\100bp）；
图3为本发明小鼠PTDSS2-CKO 5端、3端与野生型鉴定电泳图中DNA Marker条带示意图。
具体实施方式
实施例1、PTDSS2基因条件性敲除小鼠模型的构建
本实施例使用CRISPR Cas9技术对小鼠PTDSS2基因进行基因修饰，基因稳定遗传的小鼠与表达Cre重组酶的小鼠交配后，flox小鼠被敲除，敲除该区域将导致蛋白质功能被破坏。如无特别说明，本实施例采用的小鼠均为C57BL/6J品系小鼠。
1、确定条件性敲除区域及序列
根据PTDSS2基因的结构，将PTDSS2-201转录本的Exon2-Exon3作为敲除区域，该区域包含185bp的编码序列。打靶载体的序列如下所示，其中具有下划线的大写字母对应Loxp位点。
Loxp1的插入位置如下所示：
cttgaagacctgacctgggaccggccctgtccctttcttggcaacgccttcatggttccctggttggttctggcagggttgccttcctacccactcagcgatttgtcacgtcctgcacgacttaagggatccagatctgggcccacaATAACTTCGTATAGCATACATTATACGAAGTTATatgttcttgcgcaaggtcagttggtgaggagcgtggtcatctccagggaagaacaggaactgggtattttccactcagagcaaggaaccagtttgtcctcatgcctgcccctgggcagtaactg
Loxp2的插入位置如下所示：
tgctttgtcacaataaaactacatgtgtacagggacaggtgctggctgacgggtaagggcttgtcctgcatttggaggaagagagctataagcccatatgatcgcattgtctgagtacgtgATAACTTCGTATAGCATACATTA TACGAAGTTATgggccaacagaattcgatatcctgcagggactaacagaagaacgcgttgtggtaaggcaacttcctctcaagagccacatctcaaggagcatgacagatgggaccacactggccaactggcagtaacttgcttctgcaacttggctccggg
2、确定用于模型制备的sgRNA序列
根据替换片段确定sgRNA大概区域，针对目的片段选取脱靶率最低几组序列作为待选sgRNA（见下表1）。设计并合成识别5’端靶位点和3’端靶位点，并构建sgRNA表达载体。两端sgRNA识别位点分别位于小鼠PTDSS2基因的第二个外显子之前和第三个外显子之后，各sgRNA在PTDSS2上的靶位点序列（SEQ ID NO.1至SEQ ID NO.4）如下：
表1 sgRNA序列信息
sgRNA转录制备方法：以PrimerStar或PrimerStar Max体系，sgRNA-F、sgRNA-R为引物，测序正确的puc57-sgRNA质粒（1：30稀释）为模板进行PCR（PCR反应体系和反应条件如表3和表4所示），PCR产物进行纯化，制备sgRNA转录模板。使用T7-ShortScript体外转录试剂盒（AM1354）进行sgRNA的转录。
sgRNA筛选：分别将4个sgRNA与Cas9蛋白进行孵育后，将混合液注射至0.5天的受精卵中，培养至囊胚阶段后，进行小鼠PTDSS2基因的KO阳性率的鉴定，以此筛选切割活性高的sgRNA。
sgRNA切割鉴定方法：对收集的囊胚进行巢式PCR扩增，PCR扩增引物序列见表2，将扩增条带进行二代测序，与wt条带比对，统计发生突变的概率，切割效率的鉴定结果见表5。
表2 sgRNA的PCR扩增引物序列
表3 PCR反应条件
表4 PCR反应体系
表5 sgRNA切割效率
3、打靶载体构建
注射用载体由通用生物（安徽）股份有限公司合成。
4、移植注射获得阳性鼠
将打靶载体、目的sgRNA（JS25721-Ptdss2-5S1和JS25721-Ptdss2-3S1）、Cas9蛋白注射到受精卵，移植至假孕小鼠。对假孕生仔鼠（1#-13#）进行基因型鉴定，鉴定引物信息见表6，PCR反应条件和反应体系如下表7和表8所示，筛选成功插入正确人源片段的阳性鼠F0小鼠，F0鉴定结果如图1所示，其中1#、4#、10#、13#均为阳性鼠F0，使用1#阳性鼠F0继续繁育。
表6 鉴定引物信息
表7 PCR反应条件
表8 PCR反应体系
F0小鼠（1#）与背景鼠配繁获得F1，对F1代鼠尾进行基因鉴定，F1代小鼠（23#-25#）的PCR实验结果如图2所示，其中23#为阳性鼠F1。阳性鼠F1大量扩繁后进行互配，获得纯合子。
以上所述的具体实施方式，对本发明的目的、技术方案和有益效果进行了进一步详细说明，所应理解的是，以上所述仅为本发明的具体实施方式而已，并不用于限定本发明的保护范围，凡在本发明的精神和原则之内，所做的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
序列表
<110> 广东药康生物科技有限公司
<120> 一种PTDSS2条件性基因敲除小鼠模型的构建方法
<160> 16
<170> SIPOSequenceListing 1.0
<210> 1
<211> 23
<212> DNA
<213> 人工序列（Artificial Sequence）
<400> 1
ccacgctcct cacgctgagt ggg 23
<210> 2
<211> 23
<212> DNA
<213> 人工序列（Artificial Sequence）
<400> 2
agctataagc ccatatggta agg 23
<210> 3
<211> 23
<212> DNA
<213> 人工序列（Artificial Sequence）
<400> 3
cccactcagc gtgaggagcg tgg 23
<210> 4
<211> 23
<212> DNA
<213> 人工序列（Artificial Sequence）
<400> 4
gaggaagttg ccttaccata tgg 23
<210> 5
<211> 23
<212> DNA
<213> 人工序列（Artificial Sequence）
<400> 5
atagcacgct cctcacgctg agt 23
<210> 6
<211> 23
<212> DNA
<213> 人工序列（Artificial Sequence）
<400> 6
aaacactcag cgtgaggagc gtg 23
<210> 7
<211> 23
<212> DNA
<213> 人工序列（Artificial Sequence）
<400> 7
ataggctata agcccatatg gta 23
<210> 8
<211> 23
<212> DNA
<213> 人工序列（Artificial Sequence）
<400> 8
aaactaccat atgggcttat agc 23
<210> 9
<211> 23
<212> DNA
<213> 人工序列（Artificial Sequence）
<400> 9
atagccactc agcgtgagga gcg 23
<210> 10
<211> 23
<212> DNA
<213> 人工序列（Artificial Sequence）
<400> 10
aaaccgctcc tcacgctgag tgg 23
<210> 11
<211> 23
<212> DNA
<213> 人工序列（Artificial Sequence）
<400> 11
atagaggaag ttgccttacc ata 23
<210> 12
<211> 23
<212> DNA
<213> 人工序列（Artificial Sequence）
<400> 12
aaactatggt aaggcaactt cct 23
<210> 13
<211> 22
<212> DNA
<213> 人工序列（Artificial Sequence）
<400> 13
ccaagaaagc cagtgtaaca gg 22
<210> 14
<211> 23
<212> DNA
<213> 人工序列（Artificial Sequence）
<400> 14
atggtctgag tcccatgact agg 23
<210> 15
<211> 23
<212> DNA
<213> 人工序列（Artificial Sequence）
<400> 15
ggtatgctag aaaggaagga tgc 23
<210> 16
<211> 23
<212> DNA
<213> 人工序列（Artificial Sequence）
<400> 16
gaacctgcaa gtctggaaga cac 23
Claims (3)
1.一种PTDSS2基因条件性敲除小鼠模型构建方法，其特征在于，该方法包括如下步骤：
（1）设计针对鼠源PTDSS2基因Exon2-Exon3的sgRNA；
（2）利用体外转录技术获得上述sgRNA；
（3）将打靶载体、步骤（2）获得的sgRNA、Cas9蛋白共注射或共电转至小鼠受精卵细胞质或细胞核中，并将该受精卵移植至假孕小鼠，对假孕生仔鼠进行基因型鉴定，筛选成功插入正确人源片段的阳性F0小鼠；
（4）F0小鼠与背景鼠配繁获得F1小鼠，对F1代鼠尾进行基因鉴定，筛选出PTDSS2基因条件性敲除小鼠模型；
所述步骤（1）中两端sgRNA识别位点分别位于小鼠PTDSS2基因的第二个外显子之前和第三个外显子之后；
所述步骤（1）中sgRNA的基因序列为SEQ ID NO.1和SEQ ID NO.2。
2.根据权利要求1所述的小鼠模型构建方法，其特征在于，所述步骤（2）中以sgRNA-F、sgRNA-R为引物对，puc57-sgRNA质粒为模板进行PCR，PCR产物纯化制备sgRNA转录模板，并经过体外转录得到sgRNA；
所述步骤（2）中的引物对如SEQ ID NO.5和SEQ ID NO.6，以及SEQ ID NO.7和SEQ IDNO.8所示。
3.根据权利要求1所述的小鼠模型构建方法，其特征在于，所述步骤（3）中F0小鼠基因型鉴定使用的5’端鉴定引物如SEQ ID NO.13和SEQ ID NO.14所示，3’端鉴定引物如SEQ IDNO.15和SEQ ID NO.16所示。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210502574.3A CN114592011B (zh) | 2022-05-10 | 2022-05-10 | 一种ptdss2条件性基因敲除小鼠模型的构建方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210502574.3A CN114592011B (zh) | 2022-05-10 | 2022-05-10 | 一种ptdss2条件性基因敲除小鼠模型的构建方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114592011A CN114592011A (zh) | 2022-06-07 |
| CN114592011B true CN114592011B (zh) | 2022-08-05 |
Family
ID=81813614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210502574.3A Active CN114592011B (zh) | 2022-05-10 | 2022-05-10 | 一种ptdss2条件性基因敲除小鼠模型的构建方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114592011B (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006105602A1 (en) * | 2005-04-06 | 2006-10-12 | The Walter And Eliza Hall Institute Of Medical Research | Animal models and cells with a modified gene encoding transthyretin-related protein and applications thereof |
| WO2015066768A1 (en) * | 2013-11-07 | 2015-05-14 | Ozgene Holdings Pty Ltd | Compositions and methods for producing genetically modified animals |
| CN109266680A (zh) * | 2018-10-17 | 2019-01-25 | 江苏集萃药康生物科技有限公司 | 一种应用Cas9技术制备CKO/KI动物模型的方法 |
| CN111206054A (zh) * | 2020-02-14 | 2020-05-29 | 河北医科大学第三医院 | 一种利用CRISPR-Cas9条件性敲除肝脏HO-1基因动物模型的构建方法 |
| CN111961685A (zh) * | 2020-08-18 | 2020-11-20 | 江西中医药大学 | CRISPR Cas9条件性基因敲除鼠、建立方法 |
| CN112980846A (zh) * | 2021-04-09 | 2021-06-18 | 山西省人民医院 | 一种Pax2条件性基因敲除小鼠模型的构建方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5414012B2 (ja) * | 2006-01-05 | 2014-02-12 | 独立行政法人産業技術総合研究所 | 変異ｂｄｎｆ遺伝子導入ノックインマウス |
-
2022
- 2022-05-10 CN CN202210502574.3A patent/CN114592011B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006105602A1 (en) * | 2005-04-06 | 2006-10-12 | The Walter And Eliza Hall Institute Of Medical Research | Animal models and cells with a modified gene encoding transthyretin-related protein and applications thereof |
| WO2015066768A1 (en) * | 2013-11-07 | 2015-05-14 | Ozgene Holdings Pty Ltd | Compositions and methods for producing genetically modified animals |
| CN109266680A (zh) * | 2018-10-17 | 2019-01-25 | 江苏集萃药康生物科技有限公司 | 一种应用Cas9技术制备CKO/KI动物模型的方法 |
| CN111206054A (zh) * | 2020-02-14 | 2020-05-29 | 河北医科大学第三医院 | 一种利用CRISPR-Cas9条件性敲除肝脏HO-1基因动物模型的构建方法 |
| CN111961685A (zh) * | 2020-08-18 | 2020-11-20 | 江西中医药大学 | CRISPR Cas9条件性基因敲除鼠、建立方法 |
| CN112980846A (zh) * | 2021-04-09 | 2021-06-18 | 山西省人民医院 | 一种Pax2条件性基因敲除小鼠模型的构建方法 |
Non-Patent Citations (6)
| Title |
|---|
| A conditional knockout resource for the genome–wide study of mouse gene function;William C. Skarnes et al;《Nature》;20110615;第337-342页 * |
| ACCESSION NO.NM_013782，Mus musculus phosphatidylserine synthase 2（Ptdss2），mRNA;无;《GenBank》;20210929;FEATURES,ORIGIN * |
| Defining the importance of phosphatidylserine synthase 2 in mice;Martin O Bergo et al;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20021001;第277卷(第49期);第47701-47707页 摘要，试验步骤，结果部分 * |
| Skarnes,W.C.et al.ACCESSION NO.JN948659,Mus musculus targeted KO-first, conditional ready, lacZ-tagged mutant allele Ptdss2:tm1a(EUCOMM)Hmgu * |
| transgenic.《GenBank》.2011,FEATURES,ORIGIN. * |
| 利用CRISPR/Cas9技术将LoxP序列靶向引入小鼠Alk1基因;徐铭 等;《中国临床神经科学》;20151120;第23卷(第06期);第615-623页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114592011A (zh) | 2022-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106047930B (zh) | 一种PS1基因条件性敲除flox大鼠的制备方法 | |
| CN107475300B (zh) | Ifit3-eKO1基因敲除小鼠动物模型的构建方法和应用 | |
| CN108753783A (zh) | Sqstm1全基因敲除小鼠动物模型的构建方法和应用 | |
| CN107208113A (zh) | 用于通过单步多重靶向进行靶向遗传修饰的方法和组合物 | |
| US20200029538A1 (en) | Genome editing method | |
| CN110951787A (zh) | 一种免疫缺陷小鼠、其制备方法及应用 | |
| CN110551759A (zh) | 一种提高转基因细胞重组效率的组合物及方法 | |
| CN110684777B (zh) | 一段分离的核苷酸序列在肌间刺减少的斑马鱼构建中的应用 | |
| CN110643636B (zh) | 一种团头鲂MSTNa&b基因敲除方法与应用 | |
| CN108103108A (zh) | Cebpa基因缺失斑马鱼突变体的制备及其应用 | |
| CN113755498A (zh) | 靶向小鼠Ube3a基因的gRNA及构建AS疾病小鼠模型的方法 | |
| CN113736787A (zh) | 靶向小鼠Atp7b基因的gRNA及构建Wilson疾病小鼠模型的方法 | |
| CN111961685A (zh) | CRISPR Cas9条件性基因敲除鼠、建立方法 | |
| CN108300738B (zh) | 一种nod遗传背景的中性粒细胞缺失的人源化小鼠模型的制备方法 | |
| CN111549070B (zh) | 对x染色体多拷贝基因进行编辑实现动物性别控制的方法 | |
| CN113234756A (zh) | 一种基于CRISPR/Cas9技术的LAMA3基因敲除动物模型的构建方法 | |
| WO2020204159A1 (ja) | ノックイン細胞の作製方法 | |
| CN114592011B (zh) | 一种ptdss2条件性基因敲除小鼠模型的构建方法 | |
| CN116784280A (zh) | 一种tfrc人源化小鼠模型的构建方法及其应用 | |
| CN114606270B (zh) | 一种Mia3条件性基因敲除小鼠模型的构建方法 | |
| CN105440111B (zh) | 一对转录激活子样效应因子核酸酶及其编码序列与应用 | |
| CN109694885B (zh) | 基于CRISPR/Cas9技术制备PI3Kγ全身敲除模式小鼠方法及其应用和试剂盒 | |
| CN112695034A (zh) | ApoE基因缺失斑马鱼的制备 | |
| Pi et al. | Electroporation Delivery of Cas9 sgRNA Ribonucleoprotein-Mediated Genome Editing in Sheep IVF Zygotes | |
| CN115725590B (zh) | Oser1基因在提升动物生殖力或延缓生殖衰老中的应用和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |